
|Videos|June 7, 2021
Dr. Galsky on the “new dawn” in bladder-sparing in bladder cancer
Author(s)Urology Times staff
“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.
Advertisement
In a video filmed during the 2021 ASCO Annual Meeting, Matthew Galsky, MD, discusses the emergence of new bladder-sparing approaches in the treatment of bladder cancer. Galsky is Professor of Medicine (Hematology and Medical Oncology) and Acting Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System, New York City, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
3
FDA approves cefepime and zidebactam for complicated UTI
4
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
5











